LumiraDx's stock skyrockets due to a new partnership with AstraZeneca and Everton in the Community, enhancing healthcare opportunities.

HC Wainwright & Co. supports Spero Therapeutics, highlighting the potential for growth in the biotech sector with a target price of $7.